Targeted protein degradation in modern pharmacology: A comprehensive review of PROTAC technology, molecularglues, and emerging therapeutic applications
Abstract
Targeted protein degradation (TPD) has emerged as an innovative therapeutic strategy in modern pharmacology, offering a fundamentally different approach to disease management by promoting the selective elimination of disease-associated proteins rather than merely inhibiting their biological activity. Conventional pharmacological agents generally depend on sustained interactions with specific protein targets to suppress their function. In contrast, targeted protein degradation utilizes endogenous cellular protein degradation pathways to remove unwanted or pathological proteins, potentially overcoming several limitations associated with traditional drug discovery. Among the major technologies developed in this field, proteolysis-targeting chimeras (PROTACs) and molecular glue degraders have attracted considerable scientific and pharmaceutical interest. PROTACs are heterobifunctional molecules designed to simultaneously bind a target protein and an E3 ubiquitin ligase, facilitating the formation of a ternary complex that promotes ubiquitination and subsequent proteasomal degradation. Molecular glues, in comparison, are generally smaller molecules that stabilize or induce interactions between proteins, including interactions between target proteins and E3 ubiquitin ligases, resulting in selective protein degradation. These technologies have expanded the possibilities of pharmacological intervention against previously difficult-to-target proteins, particularly in oncology, inflammatory disorders, neurological diseases, and other conditions involving abnormal protein expression or function. This review examines the molecular foundations of targeted protein degradation, structural and chemical principles underlying PROTAC development, mechanisms of molecular glue activity, and emerging approaches for improving degrader selectivity and therapeutic performance. Furthermore, it discusses pharmacokinetic and pharmacodynamic considerations, formulation and drug delivery challenges, safety concerns, and the evolving clinical development landscape. Despite significant progress, limitations involving molecular size, cellular permeability, E3 ligase availability, resistance mechanisms, and tissuespecific delivery remain important barriers to clinical translation. Continued advances in medicinal chemistry, structural biology, computational drug design, and precision medicine may facilitate the development of safer and more effective protein degradation therapeutics. Overall, targeted protein degradation represents a promising advancement in pharmaceutical research, potentially transforming conventional drug discovery into a more selective, event-driven therapeutic approach.
Keywords:
Targeted Protein Degradation, PROTACs, Molecular Glue Degraders, Ubiquitin–Proteasome System, E3 Ubiquitin Ligases, Pharmacology, Drug Discovery, Precision Medicine, Protein Degradation, Targeted Therapeutics.Published
Abstract Display: 0
PDF Downloads: 0 Issue
Section
Copyright (c) 2026 SCIENXT CENTER OF EXCELLENCE(P) LTD.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.